Skip to main content

Astellas Pharma Value Stock - Dividend - Research Selection

Astellas Pharma Inc

ISIN: JP3942400007, WKN: 856273

Market price date: 28.05.2021
Market price: 1.760,50 JPY




Astellas Pharma Inc Fundamental data and company key figures of the share

Annual reports in JPY
Key figures 04-05-2021
Cash flow
Net operating cash flow 307.880.000.000
Capital Expenditures -31.384.000.000
Free cash flow 276.495.990.784
Balance sheet
Total Equity 1.386.110.000.000
Liabilities & Shareholders equity 2.273.630.000.000
Income statement
Net income 120.589.000.000
Eps (diluted) 64,900
Diluted shares outstanding 1.860.000.000
Net sales/revenue 1.249.530.000.000

Fundamental ratios calculated on: 28-05-2021

Ratios
Key figures 28-05-2021
Cash flow
P/C 10,64
   
P/FC 11,84
Balance sheet
ROI5,30
ROE60,97
Income statement
P/E27,13
Div. Yield2,39%
P/B2,36
P/S2,62


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol4503.TSE
Market Capitalization31.570.255.872,00 USD
Country
IndicesNIKKEI 225
Sectors
Raw Data SourceIFRS in Millionen JPY
Stock Split2014-03-27,5.0000/1.0000; 2014-03-26,5.0000/1.0000
Internetwww.astellas.com


Description of the company

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.astellas.com